Related Experiment Video
Updated: Aug 25, 2025

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
Epileptic spasms: A South African overview of aetiologies, interventions, and outcomes
Sharika V Raga1, Farida Essajee2, Regan Solomons2
1Paediatric Neurology Division, Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, Neuroscience Institute, University of Cape Town, Cape Town, South Africa.
Insights
Infants with epileptic spasms in South Africa often have structural causes and delayed diagnosis, but hormonal therapy like adrenocorticotropic hormone is safe and effective, even with high rates of tuberculosis and HIV.
Area of Science:
- Pediatric Neurology
- Epileptology
- Infectious Diseases
Background:
- Epileptic spasms in infants present diagnostic and therapeutic challenges, particularly in resource-limited settings endemic for tuberculosis and HIV.
- Understanding the causes and treatment outcomes is crucial for improving infant neurological health.
Purpose of the Study:
- To investigate the aetiologies of epileptic spasms in infants.
- To evaluate the safety and efficacy of high-dose corticosteroids in managing infantile spasms in a tuberculosis (TB) and human immunodeficiency virus (HIV) endemic region.
- To analyze treatment delays and developmental outcomes.
Main Methods:
- Retrospective analysis of infants diagnosed with epileptic spasms at tertiary referral centers in the Western Cape, South Africa.
- Data collection included age at onset, aetiologies, treatment received, and developmental outcomes.
- Statistical analysis was performed to compare outcomes between different groups.
Main Results:
- Structural aetiologies were the most common cause (66%) of epileptic spasms in infants.
- A shorter lead time to treatment (<1 month) was observed in infants with developmental and epileptic encephalopathy (DEE).
- Hormonal therapy, including adrenocorticotropic hormone, was safe and effective, achieving spasm resolution in 65% of cases within 14 days, despite high TB and HIV prevalence.
Conclusions:
- Despite challenges in diagnosis and referral, hormonal therapy is a viable and effective treatment for infantile epileptic spasms in resource-limited, high-burden TB/HIV settings.
- Delayed recognition of developmental delay and under-referral remain significant issues impacting timely treatment and outcomes.
- Infants with DEE showed worse developmental outcomes compared to international cohorts, highlighting the need for improved management strategies.
Aim:
To better understand the aetiologies of epileptic spasms in infants, as well as the safety and efficacy of high dose corticosteroids in tuberculosis and human immunodeficiency virus (HIV) endemic resource-limited settings.
Method:
This was a retrospective analysis of infants with epileptic spasms managed at the tertiary referral centres in the Western Cape, South Africa.
Results:
Of 175 children with epileptic spasms, the median age at onset was 6 months (interquartile range 4-8 months). Structural aetiologies were most common (115 out of 175 [66%]), with two-thirds related to perinatal insults. A lead time to treatment (LTTT) of less than 1 month was more likely in the epileptic encephalopathy/developmental and epileptic encephalopathy (DEE) group: 58 out of 92 (63%), compared to 28 out of 76 (37%) of those with developmental encephalopathy (p = 0.001). Failure to recognize preceding developmental delay was common. Ninety-nine children (57%) received first line hormonal therapy such as adrenocorticotropic hormone. A total of 111 out of 172 children (65%) from the developmental encephalopathy and epileptic encephalopathy/DEE groups had clinical and/or electroencephalogram resolution of spasms within 14 days. In our population, children in whom an aetiology could not be identified were statistically more likely to have moderate to profound developmental delay at 1 year of age: 33 out of 44 (p = 0.001). Based on reported incidence of epileptic spasms, 23 to 58 cases per annum would be expected but a far smaller proportion presented to our centres.
Interpretation:
Whilst this is the largest cohort of infants with epileptic spasms from sub-Saharan Africa, the study size is less than expected; this may reflect misdiagnosis and failure of referral pathways. Despite a reported shorter LTTT, infants with DEE had worse developmental outcomes compared to international studies. Hormonal therapy was safe and effective in our setting, despite exposure to high levels of tuberculosis and HIV.
What This Paper Adds:
The number of unreferred cases of epileptic spasms in South Africa remains high. Caregivers and health care workers in primary care facilities often fail to recognize developmental delay. The burden of disease from hypoxic-ischaemic encephalopathy remains high in our resource-limited setting. Hormonal treatment (e.g. adrenocorticotropic hormone) was safe and effective despite the high prevalence of human immunodeficiency virus and tuberculosis.
More Related Videos
09:16Use of a Wireless Video-EEG System to Monitor Epileptiform Discharges Following Lateral Fluid-Percussion Induced Traumatic Brain Injury
Published on: June 21, 2019
09:57Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
Published on: September 20, 2024
Related Concept Videos
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Seizures: Classification
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Antiepileptic Drugs: Glutamate Antagonists